Cannabigerol (CBG), which is a rare, non-intoxicating compound that other cannabinoids are extracted from, is seeing a rise in its demand and consumption in the market. Many companies such as Avicanna Inc. are exploring the compounds’ potential therapeutic advantages in terms of over-the-counter as well as pharmaceutical use. Avicanna Inc. focuses on driving its research efforts into CBG’s therapeutic promise for this less-familiar cannabinoid’s increased presence in the marketplace.
According to Avicanna’s Executive Vice President, the company is confident that CBG becoming could a common active ingredient within consumer product lines and could be a prospect for the company’s drug development platforms as an isolate as well as when combined with other cannabinoids. Avicanna is also undertaking research worldwide using CBG in various oral and topical formulations alongside undertaking in vivo and vitro research to become more aware of its possibilities and abilities for various indications.
CBG shares various properties that are similar to the CBD compound including possible anti-inflammatory aspects, possible pain properties, and possibly for nausea treatment. Also, small early studies of CBG indicate that the cannabinoid may contain anti-bacterial properties. The compound may have potential in the fight against drug-resistant superbugs including MRSA. Additionally, earlier research points out that CBG could have an effect on the growth of tumors in cell models of colorectal cancer as well as for glaucoma by minimizing intraocular pressure.